Researchers in England claim the practice - involving the most well-known breast and ovarian cancer gene mutations - is also cost-effective.
It's hoped identifying them early would stop the disease developing.
Tracie Miles is from the Hammersmith-based Eve Appeal and has welcomed the findings: